Super Bowl ad by Hims & Hers features GRAIL’s Galleri MCD test

Blood test detects lung cancer up to 5 years before scans, Personalis and University College London study finds

Personalis Inc. announced the publication of one of the largest and most comprehensive patient cohorts to date from the landmark TRACERx study, which demonstrated the clinical importance of ultrasensitive, tumor-informed molecular residual disease testing in stage 1 to 3 non-small cell lung cancer.

December 19, 2025

Vol.51 No.46

Clinical

Class action complaint alleging GRAIL insider fraud resubmitted after dismissal

Following last month’s dismissal of the securities class action complaint against Illumina Inc. and its former spinoff company, GRAIL, the plaintiffs have refiled an amended complaint, keeping the action alive.

Early endpoints are a balance of risk and benefit

Early endpoints have the potential to get effective drugs to patients faster, but granting approval to drugs—even accelerated approval—comes with the risk that ineffective or even harmful drugs will be given to patients.

October 29, 2025

Vol.51 No.39

Drugs & Targets

Exact Sciences launches Cancerguard MCED test

Exact Sciences Corp. announced the launch of the Cancerguard test, a multi-cancer early detection blood test that is now available as a laboratory-developed test in the United States.

September 19, 2025

Vol.51 No.34

In Brief

Jaime LaMontagne named chief marketing officer of Astrin Biosciences

Jaime LaMontagne was appointed chief marketing officer of Astrin Biosciences.

August 08, 2025

Vol.51 No.31

Clinical Roundup

Mailing at-home test kits is more effective at getting younger adults to participate in CRC screening, UCLA study finds

Mailing a stool-based test directly to people’s homes was the most effective of four strategies for increasing colorectal cancer screening rates, according to a study by UCLA researchers aimed at identifying the best approach to promote CRC screening in adults ages 45 to 49.

August 08, 2025

Vol.51 No.31

Super Bowl ad by Hims & Hers features GRAIL’s Galleri MCD test

YOU MAY BE INTERESTED IN

Blood test detects lung cancer up to 5 years before scans, Personalis and University College London study finds

Class action complaint alleging GRAIL insider fraud resubmitted after dismissal

Early endpoints are a balance of risk and benefit

Exact Sciences launches Cancerguard MCED test

Jaime LaMontagne named chief marketing officer of Astrin Biosciences

Mailing at-home test kits is more effective at getting younger adults to participate in CRC screening, UCLA study finds

Renew today!

Subscriber content

Never miss an issue!

Login